New Delhi: 'Gennova' has started the nomination of Volunteers for the clinical trial of HGCO 19, the first messenger RNA-based potential vaccine of Coronavirus. The Department of Biotechnology (DBT), which has funded the development of the vaccine, has given information about this on Tuesday. The department said that it has approved more funds for clinical trials of India's unique mRNA-based covid-19 vaccine, 'HGCO19'.

This vaccine is being developed by Pune-based biotechnology company Gennova Biopharmaceuticals Limited. This fund is given under DBT's 'Mission covid Suraksha'. The Department of Biotechnology Industry Research Assistance Council (BIRAC) of DBT is implementing it. DBT stated that "DBT has supported Gennova since its inception and has provided funding for the development of HGCO19 to establish its MRNA-based vaccine manufacturing platform".

Gennova has developed the coronavirus mRNA vaccine - HGCO19 in collaboration with HDT Biotech Corporation of America. This step may prove to be better for India, as with increasing cases of coronavirus infection, it can provide a more alternative to the country in fighting the global pandemic by addressing the concerns of states regarding the deficiency of corona vaccine. 

Also Read:

Gyanvapi Masjid case: Anjuman Intezamia reaches Allahabad HC to stop ASI survey

New variant of corona is not more serious, new study revealed

Chhattisgarh: Covid Hospital set up at Indoor Stadium, CM Baghel inspects